Disease-modifying drugs (DMDs) are used to slow the progression of MS and help to lessen and control relapses.
Despite this, just 44 per cent of patients continue to adhere to the treatment after two years.
Dr Paul O'Connor, director of the MS Clinic at St Michael's Hospital, said: "It is important that patients understand the need for continuing treatment in order to prevent some of the long-term consequences of MS."
He explained that some patients may stop taking the medication because they are not feeling the benefits or due to side-effects.
Meanwhile, an oral drug called laquinimod was found to delay the progression of MS in a study from the University of California San Francisco, according to HealthDay news.
Read about Barchester expertise in offering multiple sclerosis support.